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IMPLICATIONS OF GENOMICS ADVANCES FOR DRUG DISCOVERY, CLINICAL
THERAPIES, & RARE DISEASE RESEARCH
JOHN R. RAYMOND, MD
PRESIDENT & CEO AND PROFESSOR OF MEDICINE
MEDICAL COLLEGE OF WISCONSIN

The burgeoning field of genomics offers immense promise for the
transformational power of personalized medicine. Genomics is the study of the
full complement of DNA in an individual cell or organism. Personalized
medicine is the customization of health care therapies to the individual patient.
By sequencing the genome (DNA) of an individual, one can unlock the secrets
of genetic causes of rare diseases, customize therapies for specific cancer types,
and identify predispositions for complex diseases.9 The ability to sequence the
entirety of an individual’s genome, and to analyze and annotate it have
improved exponentially over the last few years, to the point that it is
conceivable, and perhaps inevitable, that anyone who wants to have their
genome sequenced will be able to do so for a relatively nominal fee within the
next few years.
The confluence of rapid, high-capacity sequencing
instruments; new bioinformatic tools; a rapidly growing catalogue of disease
mutations and allelic variations; and powerful computational resources and data
storage availability will enable disruptive innovation that will make genomics
an integral part of health care and wellness strategies in our lifetimes. The
transformative potential of genomics in personalized medicine is particularly
meaningful to us in Milwaukee, as much of the groundbreaking work has been
performed at and with the support of the Medical College of Wisconsin and
Children’s Hospital of Wisconsin.

9. Howard J. Jacob, et al., Genomics in Clinical Practice: Lessons from the Front Lines,
5(194) SCIENCE TRANSLATIONAL MEDICINE 194cm5 (2013).
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Genomics will revolutionize drug discovery in at least four ways. First, by
identifying the causes of rare diseases, scientists and clinicians will create clues
about heretofore unknown and possibly unsuspected functions of genes. These
clues will lead to new mechanistic insights that will create novel “druggable”
targets. The druggable targets should be amenable to high throughput
screening, in silico analyses and other drug discovery methodologies, which in
turn, will lead to innovative therapies.
Second, clinicians will be able to optimize drug therapy for specific
syndromes for each patient based on their genomic sequences, by choosing the
drugs that are most likely to work, and by avoiding those that can cause serious
side effects. It is now well known that a significant percentage of the
population does not obtain a therapeutic benefit from clopidogrel,10 a potent
(and expensive) anti-platelet agent used in the prevention of heart attacks and
strokes. Clopidogrel is a pro-drug that requires a certain enzyme (CYP2C19)
to become active. Genetic mutations of that enzyme impair the metabolism of
clopidogrel, rendering it ineffective. With regard to side effects, angiotensinconverting enzyme inhibitors (ACEI) are highly effective antihypertensive
drugs. But, ACEI can cause a dry cough in a significant number of patients that
can lead to non-compliance; ACEI also can cause life-threatening angioedema.
Both of these side effects have been linked to or are suspected to be associated
with specific genetic variations.
Third, by knowing genetic predispositions of each patient for various
“preventable” diseases, the patient could modify risk factors and behaviors
(diet, smoking, exercise). Those risk factors could be ameliorated directly by
drug therapies, or perhaps indirectly with the assistance of new types of
medicines or nutraceuticals that would encourage or enhance the effects of
healthy behaviors. Those medicines and nutraceuticals would be amenable to
drug discovery.
Fourth, a better understanding of the genetic bases of unwanted side effects
of drugs could lead to improved agents with intact therapeutic profiles and
reduced side effects through rational drug design or brute force screening
methods.

10. Simon Tabassome, et al., Genetic determinants of response to clopidogrel and
cardiovascular events, 360(4) N. ENGL. J. MED. 363–75 (2009).

